MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice

(2020) Paula I Gonzalez‐Ericsson et al.   JOURNAL OF PATHOLOGY

Immune Escape during Breast Tumor Progression

(2020) Carlos R. Gil Del Alcazar et al.   Cancer Immunology Research

Muc1-c in chronic inflammation and carcinogenesis;emergence as a target for cancer treatment

(2020) Donald W Kufe   CARCINOGENESIS

MUC1-C drives stemness in progression of colitis to colorectal cancer

(2020) Wei Li et al.   JCI Insight

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

(2019) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage

(2019) Dvir Aran et al.   NATURE IMMUNOLOGY

New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx

(2019) Mohamed Mounir et al.   PLoS Computational Biology

Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells

(2019) Yuxuan Miao et al.   CELL

Cancer stemness, intratumoral heterogeneity, and immune response across cancers

(2019) Alex Miranda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Current Landscape of Immunotherapy in Breast Cancer

(2019) Sylvia Adams et al.   JAMA Oncology

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

(2019) Rama Soundararajan et al.   Cancers

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study

(2019) Aurelia Noske et al.   EUROPEAN JOURNAL OF CANCER

Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation

(2019) Shabnam Shalapour et al.   IMMUNITY

TARGETING MUC1-C INHIBITS TWIST1 SIGNALING IN TRIPLE-NEGATIVE BREAST CANCER

(2019) Tsuyoshi Hata et al.   MOLECULAR CANCER THERAPEUTICS

Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer

(2019) Akira I. Hida et al.   BREAST CANCER RESEARCH AND TREATMENT

MUC1-C Activates The NuRD Complex To Drive Dedifferentiation of Triple-Negative Breast Cancer Cells

(2019) Tsuyoshi Hata et al.   CANCER RESEARCH

Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis

(2019) Melinda L. Telli et al.   CLINICAL CANCER RESEARCH

Mechanisms of immune evasion in breast cancer

(2018) Joshua P. Bates et al.   BMC CANCER

Integrating single-cell transcriptomic data across different conditions, technologies, and species

(2018) Andrew Butler et al.   NATURE BIOTECHNOLOGY

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

(2018) Flávia Castro et al.   Frontiers in Immunology

TIP: A web server for resolving tumor immunophenotype profiling

(2018) Liwen Xu et al.   CANCER RESEARCH

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq

(2018) Mihriban Karaayvaz et al.   Nature Communications

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion

(2017) Marija Mojic et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer

(2017) Woosung Chung et al.   Nature Communications

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome

(2016) Rhiannon K Beckers et al.   HISTOPATHOLOGY

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis

(2015) X. Yu et al.   Clinical & Translational Oncology

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

(2015) Annie A Wu et al.   OncoImmunology

COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients

(2014) Bar Chikman et al.   MEDICAL ONCOLOGY

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes

(2013) D Murtas et al.   BRITISH JOURNAL OF CANCER

MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial–mesenchymal transition

(2013) H Rajabi et al.   ONCOGENE

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches

(2012) D W Kufe   ONCOGENE

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer

(2010) Sharon A Glynn et al.   BMC CANCER

Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer

(2009) N Khodarev et al.   ONCOGENE